Turn evidence into a strategic advantage.
Live data is only the beginning. Comphas brings trusted clinical-trial sources, your own company knowledge, visual decision tools and secure collaboration together, so teams move from evidence to a strategic call without losing context.
- Ulcerative colitis8628 in P3
- Crohn's disease5327 in P3
- UC and Crohn's188 in P3
- Eosinophilic GI73 in P3
- Celiac disease50 in P3
ClinicalTrials.gov, pulled 11 Sep 2026. Interventional, industry lead sponsor, Phase 1–3, recruiting, not yet recruiting, active or by invitation (n = 169). Multi-phase trials placed at the highest phase. Dot positions within a band are for display.
Search: query FDA and EMA clinical-trial data live, without exporting and cleaning.
Ask the registry. Get a chart.
Type a question about clinical trials. AI reads it into filters you can see; the counts come straight from ClinicalTrials.gov, with the source and date on the chart.
It answers what the registry can answer. For anything more, such as your own data next to the field, frozen evidence and decision rooms, that's what Comphas is for.
AI reads your question into filters; every number comes straight from the ClinicalTrials.gov API. Don't enter personal or confidential information.
Landscape work is right on the day and indefensible three months later.
Nobody can say what was counted, on what date, from which source, or by whom. It is a commercial problem before it is a compliance one.
The registry has moved.
New starts, status changes and results since the analysis was made.
The query can't be reproduced.
Nobody wrote down the filters behind the count.
The numbers no longer match.
The count on slide 6 disagrees with the source.
The author has left.
The reasoning left with them.
Direct cost of every day a Phase 3 decision waits. A portfolio call is only as good as your ability to say, under challenge, what the landscape was.
Tufts Center for the Study of Drug Development (Smith, DiMasi & Getz), cost-of-a-delay-day estimates, 2024, in 2023 USD.
Make the freeze explicit. The moment an analysis becomes a deliverable, the data behind it stops moving: deliberately, visibly, and with a record of when and from where.
Secondary sources direct the search. Primary sources decide.
Registries, labels and filings are fast, broad and auditable, and they repeat what competitors chose to publish. Intent, capacity and timing live with people. Comphas runs the record so your team knows where to spend its scarce conversations, and holds what they bring back to the same standard of evidence.
The record aims the primary effort; the primary effort decides
Secondary sources direct the search. Primary sources decide.
One conversation is an anecdote; three independent ones are a finding. Comphas plans congress coverage and contact questions, captures the 48-hour debrief, grades every source and item, and lets only confirmed findings into a decision case.
Aim the primary effortWhat a GI team learns in minutes.
Three key questions, answered on ClinicalTrials.gov data pulled on 11 September 2026. Every exhibit states its slice, its date and its source.
7 of 10 active EoE trials reach primary completion in 2026
ClinicalTrials.gov API v2, pulled 17 Oct 2026: active interventional Phase 1–3 trials in eosinophilic esophagitis, all sponsor classes (n = 10), ordered by primary completion. ✓ = actual date, est. = estimated; a red outline marks an estimate not verified in over a year. Scroll sideways on small screens.
Germany pairs deep Crohn's experience with light competition
Competing (recruiting) trials per 10 completed. Industry-sponsored interventional Phase 2–3 Crohn's disease trials with at least one site in the country; a multinational trial counts in every country it runs in. A registry proxy for experience and competition, not a feasibility survey.
The read: shortlist Germany first. Crowding in the bullseye above is real too: 63 of the 157 IBD trials are already in Phase 3, while celiac disease has five trials and none in Phase 3. That's an opportunity to qualify, not yet white space.
Explore the use-case libraryEvery question gets the chart that fits it.
Comphas carries 91 chart types in seven families: landscapes and timelines, comparisons, flows, networks, geography, analyst methods and more. Each one comes with a rule for when to use it, and is matched to the use cases it answers.
Crowding reads best as a heatmap. Concentration reads best as a Pareto. Status mix fits a donut, until there are more than four slices.
Live while you explore. Frozen when you decide.
Saving a chart freezes its dataset. Shipping a pack freezes every dataset on the board. Frozen data is never overwritten, not by a user and not by the nightly refresh.
What was counted, on what date, from which source: answered by the product, not by memory.
Phase 3 counts as of 11 Sep 2026. The live movement before the freeze is illustrative.
Evidence, discussion and decision stay together.
Secure rooms and chats are private spaces for strategy, go/no-go calls and confidential input. The views sit in the room with the people deciding.
A decision case freezes what the board showed on the day, and the audit log records who queried, exported or froze what.
Illustrative conversation.
AI proposes. The analyst decides. Comphas records.
Registry data is noisy: one sponsor under a dozen spellings, conditions in free text, missing mechanisms of action. Comphas uses AI to suggest the clean-up, the right chart and a draft reading of it.
Every suggestion is a proposal with a confidence score, checked against reference vocabularies, approved by an analyst and logged. Nothing changes the evidence silently.
Illustrative example of the workflow with sample data.
Keep the tools you run. Add the place where you make the call.
Power BI, Tableau, Veeva, Cortellis and IQVIA show what the field is doing. Comphas sits on top as the decision layer.
Prove it on one live programme.
Eight weeks, one programme, success criteria agreed up front.